Joseph O’Connell

3.3k total citations · 1 hit paper
41 papers, 2.5k citations indexed

About

Joseph O’Connell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Joseph O’Connell has authored 41 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Joseph O’Connell's work include Lung Cancer Treatments and Mutations (24 papers), Colorectal Cancer Treatments and Studies (18 papers) and HER2/EGFR in Cancer Research (12 papers). Joseph O’Connell is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Colorectal Cancer Treatments and Studies (18 papers) and HER2/EGFR in Cancer Research (12 papers). Joseph O’Connell collaborates with scholars based in United States, South Korea and Spain. Joseph O’Connell's co-authors include Mark G. Kris, Fergus Shanahan, Terence M. O’Connor, Triona Goode, C. P. Bredin, Richard J. Gralla, Ian W. Taylor, M. S. Wertheim, Pasi A. Jänne and Jane Liang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Joseph O’Connell

41 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The role of substance P in inflammatory disease

2004 620 citations Terence M. O’Connor, Joseph O’Connell et al. Journal of Cellular Physiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph O’Connell United States	21	1.3k	1.2k	649	372	268	41	2.5k
Yen‐Lin Chen United States	35	1.0k 0.8×	1.4k 1.1×	1.0k 1.6×	492 1.3×	266 1.0×	128	3.3k
Luka Brčić Austria	31	606 0.5×	882 0.7×	563 0.9×	655 1.8×	143 0.5×	143	2.5k
Fernando Bittinger Germany	27	727 0.6×	557 0.4×	791 1.2×	690 1.9×	167 0.6×	54	2.7k
Sylvie Lantuéjoul France	23	810 0.6×	998 0.8×	596 0.9×	297 0.8×	367 1.4×	66	2.3k
Masato Fujii Japan	32	834 0.7×	677 0.5×	818 1.3×	667 1.8×	282 1.1×	216	3.1k
Gianluigi Lunardi Italy	25	801 0.6×	408 0.3×	317 0.5×	189 0.5×	117 0.4×	68	1.9k
Pascale Marcorelles France	29	498 0.4×	311 0.3×	762 1.2×	328 0.9×	424 1.6×	138	2.6k
Enric Condom Spain	37	533 0.4×	636 0.5×	1.7k 2.6×	919 2.5×	135 0.5×	106	3.6k
Remedios Ramı́rez Mexico	30	346 0.3×	1.5k 1.2×	842 1.3×	413 1.1×	399 1.5×	74	2.9k
Yusuke Inoue Japan	22	686 0.5×	510 0.4×	744 1.1×	457 1.2×	227 0.8×	148	2.2k

Countries citing papers authored by Joseph O’Connell

Since Specialization

Citations

This map shows the geographic impact of Joseph O’Connell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph O’Connell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph O’Connell more than expected).

Fields of papers citing papers by Joseph O’Connell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph O’Connell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph O’Connell. The network helps show where Joseph O’Connell may publish in the future.

Co-authorship network of co-authors of Joseph O’Connell

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph O’Connell. A scholar is included among the top collaborators of Joseph O’Connell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph O’Connell. Joseph O’Connell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Connell, Joseph & Gary M. Weiner. (2017). Intubating extremely premature newborns: a randomised crossover simulation study. BMJ Paediatrics Open. 1(1). e000157–e000157. 1 indexed citations

Kim, Dong‐Wan, Edward B. Garon, Aminah Jatoi, et al.. (2017). Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer. 106. 76–82. 12 indexed citations

Calvo, Emiliano, Jean‐Charles Soria, Wen Wee, et al.. (2016). A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. Clinical Cancer Research. 23(5). 1177–1185. 29 indexed citations

Lacouture, Mario E., Dorothy Keefe, Stephen T. Sonis, et al.. (2016). A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Annals of Oncology. 27(9). 1712–1718. 49 indexed citations

Kris, Mark G., D. Ross Camidge, Giuseppe Giaccone, et al.. (2015). Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Annals of Oncology. 26(7). 1421–1427. 221 indexed citations

Giri, Nagdeep, Joanna C. Masters, Anna Plotka, et al.. (2015). Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. Investigational New Drugs. 33(4). 931–941. 19 indexed citations

Ramalingam, Suresh S., Pasi A. Jänne, Tony Mok, et al.. (2014). Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. The Lancet Oncology. 15(12). 1369–1378. 111 indexed citations

Ramalingam, Suresh S., Pasi A. Jänne, Tony Mok, et al.. (2014). Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).. Journal of Clinical Oncology. 32(15_suppl). 8018–8018. 13 indexed citations

Park, Keunchil, Byoung Chul Cho, Dong‐Wan Kim, et al.. (2014). Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial. Journal of Thoracic Oncology. 9(10). 1523–1531. 20 indexed citations

10.

Giri, Nagdeep, Anna Plotka, Yali Liang, et al.. (2013). Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib.. Journal of Clinical Oncology. 31(15_suppl). 2568–2568. 2 indexed citations

11.

Kris, Mark G., Zelanna Goldberg, Pasi A. Jänne, et al.. (2012). Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers. Annals of Oncology. 23. ix400–ix401. 18 indexed citations

12.

Ruiz-Garcı́a, Ana, Pasi A. Jänne, Keunchil Park, et al.. (2012). EGFR status and daily dose: Effect on tumor growth inhibition in cancer patients treated with dacomitinib (PF-00299804).. Journal of Clinical Oncology. 30(15_suppl). e18093–e18093. 3 indexed citations

13.

Boyer, Michael, Fiona Blackhall, K. Park, et al.. (2010). Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).. Journal of Clinical Oncology. 28(18_suppl). LBA7523–LBA7523. 43 indexed citations

14.

Jänne, Pasi A., Karen L. Reckamp, Marianna Koczywas, et al.. (2009). Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. Journal of Clinical Oncology. 27(15_suppl). 8063–8063. 36 indexed citations

15.

Bennett, Michael, Catherine B. Molloy, Aileen Houston, et al.. (2006). Bcl-xL expression in vivo in rheumatoid synovium. Clinical Rheumatology. 25(6). 789–793. 30 indexed citations

16.

O’Connor, Terence M., et al.. (2004). The role of substance P in inflammatory disease. Journal of Cellular Physiology. 201(2). 167–180. 620 indexed citations breakdown →

17.

O’Connor, Terence M., Joseph O’Connell, Michael Bennett, et al.. (2003). Upregulation of Neurokinin-1 Receptor Expression in the Lungs of Patients with Sarcoidosis. Journal of Clinical Immunology. 23(5). 425–435. 10 indexed citations

18.

Kris, Mark G., Richard J. Gralla, M. S. Wertheim, et al.. (1988). Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.. PubMed. 48(19). 5573–9. 51 indexed citations

19.

Kris, Mark G., Joseph O’Connell, & R. Gralla. (1986). Phase I trial of taxol given as a 3-hour infusion every 21 days. Journal of Ethnopharmacology. 18(3). 299–299. 40 indexed citations

20.

O’Connell, Joseph, Mark G. Kris, & R. Gralla. (1985). Phase I trial of taxol given as a three hour infusion every three weeks. Proceedings of the American Association for Cancer Research. 26. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact